Press Releases | October 12, 2021 |

Visiopharm announces Christian Kaltoft as Chief Operating Officer

Visiopharm is pleased to announce the appointment of Christian Kaltoft as Chief Operating Officer (COO).

Christian joins with over 15 years of experience in the pharma and life science industry. For the last eight years Christian has worked at Agilent Technologies in a variety of leadership positions within Agilent’s cancer diagnostic division. Agilent is a leading company within tissue-based cancer diagnostic and companion diagnostic. Most recently he was director of diagnostic hardware and software portfolio within global pathology marketing.

Before Agilent, Christian held positions in pharma within medical, sales and marketing, which provides Christian with a deep understanding of both the pharma, diagnostic and critical interface that enables precision medicine.

Christian takes over from current COO Thomas Ahl who will retire in the new year. Thomas has been at Visiopharm since February 2018, during which time he contributed heavily to the transformation of Visiopharm into a global and scalable business. “Thomas has been instrumental in transforming Visiopharm into a truly scalable enterprise with global presence, and we are very grateful to him for his role in this critical part of our journey,” said Michael Grunkin, CEO of Visiopharm.

Visiopharm CEO, Michael Grunkin said:

“We are very pleased that Christian is joining us at a time where we are embarking on this next exciting phase of our journey towards becoming a global tissue-diagnostic company. He is bringing a deep understanding of the market needs, where in the tissue diagnostic workflows AI can move the needle on productivity and precision, and from a cross-functional perspective, how Visiopharm can most efficiently deliver on all those parameters.”

Christian Kaltoft said:

“I’m excited to be joining Visiopharm at such a pivotal time. I have evaluated the digital pathology market and the continuous evolution. Visiopharm are one of very few AI companies in the pathology space with a proven commercial track record in the diagnostic market with a footprint of 75 diagnostic pathology labs throughout many countries. I believe that Visiopharm is very well-positioned to lead the next evolution that will enable improved standardization and expand clinical utility of image analysis in routine diagnostic setting.”

Share this article

Share the link on Twitter Share the link on LinkedIn
Learn everything about digital pathology

Latest news

Your message has been successfully sent!